CommercialCoverageMedium impact
08.00.50ae, Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®)
Independence Blue Cross·Rheumatology, Oncology, Hematology +1 more·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.50ae regarding Rituximab (Rituxan®), biosimilars, and Rituxan Hycela® was reissued effective 10/29/2025. Without access to the full policy text content, the specific coverage, billing, or authorization changes cannot be determined. The billing team must review the complete policy document to identify what changed from the previous version.
Action Required
By 10/29/2025: Billing team must obtain and review the complete policy text for 08.00.50ae at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=10&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-50ae to identify specific changes from the previous version. Compare the reissued policy against the prior version to identify: (1) any new or changed prior authorization requirements, (2) affected HCPCS/CPT codes, (3) coverage restrictions or approvals, and (4) documentation requirements. Once reviewed, update billing software rules, prior auth workflows, and provider communication accordingly. Failure to implement required changes may result in claim denials for rituximab infusions and subcutaneous injections.